Background: Development is ongoing to increase the serotype coverage of pneumococcal conjugate vaccines. We report here the immunogenicity and safety of a new 11-valent pneumococcal conjugate vaccine (Pn-PD) in infants. Methods: In a randomized, single blind study, 154 Finnish infants received 1 of 3 regimens: 4 doses of Pn-PD at 2, 4, 6 and 12-15 months; 3 doses of the Pn-PD at 2, 4 and 6 months and 1 dose of 23-valent polysaccharide vaccine (PncPS) at 12-15 months; or 3 doses of the hepatitis B vaccine at 2, 4 and 6 months and Pn-PD at 12-15 months. Serum IgG antibodies to vaccine serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F were measured with an enzyme immunoassay at the ages of 2, 7 and 12-15 months and at 4 or 28 days after the last vaccination. Local and systemic reactions were recorded by parents during 8 days after each dose. Serious adverse reactions were recorded during the entire study period. Results: There was a significant increase in the IgG concentrations to vaccine serotypes after 3 doses of Pn-PD. Antibody concentrations after the primary series varied between 1.26 and 4.92 g/ml depending on the serotype and study group. PncPS vaccine induced a better booster response than the Pn-PD, measured at 28 days after the fourth dose. IgG concentrations after the Pn-PD booster ranged between 1.60 and 9.63 g/ml and after the PncPS booster between 4.24 and 40.54 g/ml, depending on the serotype. The antibody concentrations after the first dose of Pn-PD administered at 12-15 months increased significantly but were lower than after the fourth dose at the same age. No significant antibody increase was measured 4 days after the vaccinations at 12-15 months. The safety profile of the vaccine was acceptable.
D
uring the past 10 years, an array of polysaccharideprotein conjugate vaccines against Streptococcus pneumoniae with differing carrier proteins and polysaccharide (PS) compositions have been studied. 1 One of these vaccines, a 7-valent vaccine with a CRM 197 carrier protein (PncCRM), has been granted marketing authorization in the United States, in the European Union, in Australia and in several other countries.
The only available pneumococcal conjugate vaccine, PncCRM (Prevenar/Prevnar), has been effective in preventing invasive pneumococcal infections in the United States. 2 In high risk populations, American Indians and human immunodeficiency virus-infected children, the efficacy of 7-and 9-valent formulas (respectively) has been good against invasive pneumococcal infections. 3, 4 In Finland, PncCRM was moderately efficacious against vaccine type acute otitis media. 5 The 7-valent PncCRM contains serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. It is missing serotypes 1 and 5, which are common in developing countries. 6, 7 In Asia, an increase from 7-to 11-valent vaccine by adding serotypes 1, 3, 5 and 7F widened the serogroup coverage of the vaccine against invasive pneumococcal infections from ϳ45% to 76% in young children. 8 The carrier proteins used in the experimental and licensed pneumococcal conjugate vaccines have been the same as those used in the Haemophilus influenzae type b (Hib) conjugate vaccines: CRM 197 , diphtheria toxoid, tetanus toxoid and Neisseria meningitidis outer membrane protein complex. 9 However, the increase in the load of a carrier might influence the immunogenicity of other concomitantly injected conjugate vaccines that use the same protein carrier 10 and the pneumococcal conjugate vaccine itself. 11 A recombinant non-lipidated form of the protein D (PD) from H. influenzae has been used in experimental Hib conjugate vaccines, 12 and this protein has been conjugated to pneumococcal polysaccharides. 13 PD is a highly conserved 42-kDa cell surface lipoprotein of H. influenzae. In rats, PD induces systemic and local antibodies to PD, 14 and immunization with PD has induced protection against H. influenzae otitis media in rat and chinchilla models. 15, 16 This vaccine could probably induce immunity against pneumococcus and H. influenzae.
It is recommended that the immunogenicity of new pneumococcal conjugate vaccines is evaluated by measuring antibody concentrations after the third dose. 17 The end point would be the immune response after the primary series (usually 3 doses) of the vaccines by calculating the proportions of children with antibody concentration Ն0.35 g/ml when using enzyme immunoassay (EIA) without adsorption with 22F polysaccharide. This threshold has been proposed in the recent WHO meeting of experts 18 as the primary endpoint for demonstration of immunologic noninferiority in head-tohead comparison trials that use a registered pneumococcal conjugate vaccine as a comparator. Other measures of immune response should be taken into consideration as secondary end points. These are the geometric mean concentrations at various ages, persistence of antibodies and the induction of immunologic B cell memory. 17 The induction of memory can be evaluated by the antibody response after a booster dose of pneumococcal polysaccharide vaccine (PncPS) in agematched primed and unprimed subjects, but in several pneumococcal conjugate vaccine studies immune memory has been assessed after primary series by the PncPS and or the pneumococcal conjugate response, and the immune memory response has been evaluated at days 7-10 after vaccination. 19, 20 There are to date no data showing that primed children respond more quickly after boosting with polysaccharide or conjugate vaccine than unprimed children.
We report here immunogenicity and safety of a new 11-valent pneumococcal conjugate vaccine (Pn-PD) using H. influenzae protein D as a carrier. The Pn-PD was given at 2, 4, 6 and 12-15 months of age. Immunogenicity was assessed by measuring IgG antibody concentrations after the third vaccine dose and by demonstration of the development of immunologic memory. To this end, the immune response to the fourth dose, either Pn-PD or PncPS vaccine, given at 12-15 months was measured at days 4 and 28 after vaccination and compared with that after the first dose of Pn-PD at the same age.
SUBJECTS AND METHODS
This was a randomized, single blind, controlled phase II study to evaluate the immunogenicity and safety of the 11-valent Diphtheria-tetanus-acellular pertussis-inactivated polio-Hib vaccine (Infanrix-Polio ϩ Hib; Glaxo SmithKline) was given at 2, 4 and 6 months concomitantly with the pneumococcal vaccines or the control vaccine, but at a separate injection site (opposite limb). Subjects did not receive any other vaccinations during the study period. Serologic Methods. For assessing the immune response after the primary series of 3 doses of Pn-PD, venous blood samples were taken at the ages of 2 and 7 months. For measuring the antibody response to the booster vaccination, blood samples were taken before and 4 or 28 days after the vaccinations given at 12-15 months. Serum was separated by centrifugation and samples were stored at Ϫ20°C until analyzed.
Antipneumococcal IgG concentrations to serotypes included in the vaccine were measured at the Vaccine Immunology Laboratory at KTL by EIA without adsorption with 22F polysaccharide. 21, 22 For coating with type 3 PS, methylated human serum albumin (5 g/ml) was added to the coating solution to promote binding to microtiter plates. 23 The results for serum antipneumococcal PS IgG are given in micrograms/ml). The detection cutoffs were 0.06 g/ml for type 4, 0.07 g/ml for type 18C, 0.08 g/ml for types 9V and 23F, 0.09 g/ml for types 3 and 6B, 0.1 g/ml for types 1 and 7F, 0.15 g/ml for type 5, 0.16 g/ml for type 19F and 0.19 g/ml for type 14. Safety Evaluation. The parents or guardians recorded local and systemic reactions on a diary card during 8 days after each vaccine dose. The followed reactions were pain, redness and swelling; drowsiness; fever; irritability/fussiness; and loss of appetite. Serious adverse events were recorded during the entire study period. A serious adverse event was defined as any untoward medical occurrence resulting in death, a life-threatening condition, persistent or significant disability, hospitalization or prolongation of existing hospitalization. Statistical Methods. Sample size was calculated to provide at least 89% power to detect a difference between the combined groups 1 and 2, and group 3 in terms of geometric mean concentrations of antipneumococcal polysaccharide antibodies for 11 serotypes 1 month after the third dose. Serum antibody data were log-transformed for statistical analyses. A paired t test was used to compare responses within the groups. Differences in antibody concentrations among the vaccination groups were determined by analysis of variance and independent-sample t test. p Ͻ 0.05 was considered significant. The results are given as geometric mean concentrations (GMC) with 95% confidence intervals. When concentration was below the detection limit, a value one-half of the cutoff was used to compute GMC. We also calculated the percentages of children with antipneumococcal PS IgG concentration Ն0.35 g/ml. A descriptive analysis was applied to all safety variables.
RESULTS

Antibody Concentrations to the 11 Vaccine Serotypes
Before and After the Primary Series. At the age of 2 months, antipneumococcal PS IgG concentrations were similar in the 3 groups, and the GMCs varied between 0.09 (4, group 1) and 0.40 g/ml (19F, group 2), depending on the serotype and group (data not shown). The children in groups 1 and 2 had significantly higher antipneumococcal PS IgG concentrations for all vaccine serotypes after 3 doses of Pn-PD at 7 months than before any dose at 2 months of age (P Ͻ 0.001 for all serotypes). In contrast, the children who had not received a pneumococcal vaccine had lower (P Ͻ 0.001 for all serotypes) antipneumococcal PS IgG concentrations at 7 months than at 2 months (data not shown). The 7-month concentrations were also lower than those measured at the same age in groups 1 and 2 (P Ͻ 0.001; Table 2 ). The threshold of Ն0.35 g/ml was reached by 86 -100% of the infants in groups 1 and 2 and by 0 -12% in group 3 (Table 3) . Among the Pn-PD recipients, the highest concentrations were induced for types 14 and 19F .
By 12 months of age, the antipneumococcal PS IgG concentrations in groups 1 and 2 decreased compared with those at 7 months. In group 3, the antibody concentrations remained at essentially the same level from 7 to 12 months of age ( Table 2 ). The proportions of children with antibody concentrations of Ն0.35 g/ml at 12 months ranged from 59 to 98% in groups vaccinated with 3 doses of Pn-PD. In (Table 3) . Serum samples were taken either 4 or 28 days after pneumococcal vaccination at 12-15 months (ie, either the 4th dose of Pn-PD, a dose of PncPS or the first dose of Pn-PD). In the samples taken 4 days after the fourth vaccination, the antibody concentrations were similar to those detected in samples obtained just before vaccination, and the individual increases were minimal and few (data not shown). Twentyeight days after the vaccination, antipneumococcal IgG concentrations were higher than the pre-fourth vaccination concentrations for all serotypes in every vaccine group ( Table 2) . The GMCs were significantly lower in group 3 than in groups 1 and 2, except for serotype 3. In general, the highest GMCs were found in group 2 subjects who received PncPS vaccine at 12-15 months (Table 2) . Proportions with antibody concentrations of Ն0.35 g/ml varied depending on the serotype between 96 and 100%, 91 and 100% and 20 and 100%, in groups 1, 2 and 3, respectively (Table 3) . Safety. Mild local reactions were common and usually more frequently recorded after the first 3 doses of Pn-PD than after the corresponding dose of hepatitis B vaccine. Mild systemic reactions were common in all study groups. Severe reactions were few. During the study, there were 28 serious adverse events, and none was considered to be caused by the study vaccine. Local Reactions. Within 8 days of each of the first 3 doses, local reactions were more common in children who received Pn-PD than in those who received hepatitis B vaccine (Table  4) . Local pain preventing normal daily activities was rare in all groups and reported in fewer than 6% of the children after each of the first 3 doses. PncPS vaccine, as the fourth given after 3 doses of Pn-PD, seemed to cause more local redness and swelling than the fourth dose of Pn-PD (Table 4) . Table 1 . † Pain was considered to be of grade 3 intensity if it prevented normal activity.
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Systemic Reactions. Mild drowsiness, irritability and loss of appetite were common in all 3 study groups. Irritability preventing normal daily life was reported similarly in all groups, in fewer than 6% of the children. Drowsiness preventing normal activity or complete loss of appetite was not recorded after any dose during the 8-day routine follow-up (Table 5) . Fever reactions (Ͼ38°C) were more frequently recorded during the primary series of Pn-PD (27.5-49.0%) than during the primary series of hepatitis B vaccine (9.6 -27.5%). Fever reactions seemed to increase by age and were recorded in all vaccine groups more often after the fourth than after the first vaccination (Table 5 ).
DISCUSSION
We found that the 11-valent Pn-PD conjugate vaccine was immunogenic and safe in infants. Three doses of Pn-PD induced a clear antibody response when compared with a control vaccine. After the fourth dose of the Pn-PD, there was a significant booster response as shown by the higher Pn-PD and PncPS response observed in the primed groups 1 and 2, than the Pn-PD response observed in the unprimed study group 3.
Three doses of Pn-PD induced similar immune responses in the current study as in a previous study in the Philippines, using a 6-10-14-week immunization schedule. 13 The immune response was comparable with other experimental pneumococcal conjugate vaccines studied in infants in Finland. There are, however, notable serotype specific differences in antibody profiles among various vaccines 5,24 -27 ; eg after 4 doses of pneumococcal conjugate vaccine, geometric mean IgG concentration to serotype 18C varied between 1.41 and 7.8 g/ml depending on the vaccine.
Children in group 3 received their first dose of Pn-PD at 12-15 months of age. The antibody concentrations measured in these children indicate 2 results: (1) even 1 dose of Pn-PD can induce an antibody increase in toddlers for most of the 11 serotypes but not for types 6B and 23F; (2) antibody concentrations were significantly lower than after 4 doses of the Pn-PD.
Children in group 2 received PncPS vaccine after 3 doses of Pn-PD. PncPS boosting is believed to give information about the development of B cell memory and to mimic a natural contact with pneumococcus. The antibody concentrations were high for all serotypes, even higher than after the Pn-PD booster. Hence we can assume that Pn-PD evoked the development of memory B cells that were then triggered by PS for antibody production. The significantly higher antipneumococcal antibody concentrations induced by PncPS booster than by Pn-PD booster might be caused by the higher PS content in the PncPS than in the Pn-PD vaccine. The same has been reported earlier with other pneumococcal conjugate vaccines. 19, 26, 28 In any case, it is apparent that the 3 doses of Pn-PD primed the children efficiently, except for serotype 3.
Previous studies have shown that there is a brisk antibody response on days 7-10 to a booster vaccination with either PncPS or a conjugate vaccine. 19, 20 We wanted to see whether the antibody increase can be seen even earlier. To *Drowsiness and irritability were considered to be of grade 3 intensity if they prevented normal activity. Loss of appetite was considered to be of grade 3 if the child was not eating at all. † For groups 1, 2 and 3, see Table 1 .
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The Pediatric Infectious Disease Journal • Volume 23, Number 11, November 2004 this end, we took a blood sample on day 4 after vaccination at 12-15 months, but the antibody concentrations were still essentially the same as before the 4th vaccination. Thus no antibody response could be seen as early as 4 days after vaccination although a clear cut booster response was demonstrated at 28 days. This indicates that serum samples taken at 4 days are not useful for evaluating the immune responses after booster vaccination. The local and systemic reaction rates after vaccination with Pn-PD were similar to those seen in Finnish infants vaccinated with other pneumococcal conjugate vaccines. 5, 26 As with other pneumococcal conjugate vaccines, administration of Pn-PD was followed by local reactions and fever more often than was administration of hepatitis B vaccine. PncPS given after 3 doses of Pn-PD was relatively reactogenic: redness and swelling with a diameter of Ͼ30 mm were seen in 13.7 and 7.8%, respectively; and fever higher than 39°C occurred in almost 10%. This is noteworthy because in a previous study, 26 PncPS, when given after 3 doses of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine, caused redness and swelling exceeding 25 mm in fewer than 1% and fever higher than 39°C in fewer than 1% of the vaccinees.
Well-characterized and predictive laboratory correlates are needed because of the expense, difficulty and ethical issues involved in conducting further efficacy trials. The measures for predicting the efficacy of a vaccine are difficult to estimate. At the moment, a threshold antibody concentration of Ն0.35 g/ml (determined without adsorption with 22F polysaccharide) after the primary series has been proposed as a primary endpoint when comparing a new pneumococcal conjugate vaccine with a licensed vaccine. 18 In this study, almost 100% of the children achieved the 0.35 g/ml threshold concentration of antibodies to 9 serotypes after the first 3 doses measured with the non-22F EIA. As for serotypes 6B and 23F, ϳ90% of infants achieved this concentration. The functional activity (opsonophagocytic activity and avidity) and the ability to induce immunologic memory are important secondary endpoints. 17, 29 The opsonophagocytic activity of the Pn-PD antibodies in our subjects will be reported later.
We have shown that a novel 11-valent vaccine is well-tolerated and immunogenic. Presently there is only 1 licensed pneumococcal conjugate vaccine available for general use. The licensed vaccine contains 7 pneumococcal serotypes and an increase in the coverage would be beneficial in many countries. The efficacy of this vaccine against acute otitis media caused by vaccine serotypes and by nontypable H. influenzae is now tested in the Czech Republic and in the Slovakian Republic. In the Czech Republic, an 11-valent vaccine would cover 75% of the pneumococcal acute otitis media instead of a 51% coverage of a 7-valent vaccine. 30 The shortage in the supply of the licensed vaccine 31, 32 supports further the need for licensure of new pneumococcal conjugate vaccines in the market.
